Sickle cell gene-editing treatment poised for FDA approval

The FDA is close to a decision on a landmark one-time gene-editing treatment for patients with sickle cell disease and another blood disorder. Host Kelly Hooper talks with POLITICO health care reporter Lauren Gardner about how the therapy works, its safety profile, who will be eligible for it and the significant challenges around affordability and access.